score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4222	334.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	118.0	0.4661	1.0	NRAS p.Q61R (Missense)	1.0	MEL-IPI_Pat119	MEL-IPI_Pat119-Tumor-SM-7459N	MEL-IPI_Pat119-Normal-SM-7459Q
Putatively Actionable	Preclinical	Preclinical		Copy Number	MIR17HG	Amplification				0.0	0.0		Putatively Actionable	Neoadjuvant chemotherapy + surgery	Chemotherapy + Surgical removal	Combination therapy	Amplification of the 13q31-34 region, which contains MIR17HG, was associated with increased sensitivity to neoadjuvant chemotherapy and surgery in 41% of participants in a 120-patient study.	Molinari C, Salvi S, Foca F, et al. miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. Onco Targets Ther. 2016;9:2735-42.	https://doi.org/10.2147/OTT.S105760	Investigate Actionability	Neoadjuvant chemotherapy + surgery	Chemotherapy + Surgical removal	Combination therapy	Deletion of the 13q31-34 region, which contains MIR17HG, was associated with resistance to neoadjuvant chemotherapy and surgery in 41% of participants in a 120-patient study.	Molinari C, Salvi S, Foca F, et al. miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. Onco Targets Ther. 2016;9:2735-42.	https://doi.org/10.2147/OTT.S105760						0				MIR17HG Amplification		MEL-IPI_Pat119	MEL-IPI_Pat119-Tumor-SM-7459N	
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	PRMT5 inhibition	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214													0				CDKN2A Deletion		MEL-IPI_Pat119	MEL-IPI_Pat119-Tumor-SM-7459N	
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.E480K	0.3834	193.0	0.000305	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137						0	0.0	0.0	0.0	RET p.E480K (Missense)		MEL-IPI_Pat119	MEL-IPI_Pat119-Tumor-SM-7459N	MEL-IPI_Pat119-Normal-SM-7459Q
Investigate Actionability	Clinical evidence			Copy Number	EGFR	Deletion				0.0	0.0		Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Amplification and mutation of EGFR was associated with better clinical outcomes in a trial of 66 non-small cell lung cancer patients who had experienced relapse after surgery.	Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23(28):6829-37.	https://doi.org/10.1200/JCO.2005.01.0793													0				EGFR Deletion	1.0	MEL-IPI_Pat119	MEL-IPI_Pat119-Tumor-SM-7459N	
Biologically Relevant				Rearrangement	MTOR	Fusion	MTOR--YME1L1			0.0	0.0																					0				MTOR--YME1L1 Fusion		MEL-IPI_Pat119		
Biologically Relevant				Rearrangement	JAK2	Fusion	JAK2--RBM26			0.0	0.0																					0				JAK2--RBM26 Fusion		MEL-IPI_Pat119		
Biologically Relevant				Rearrangement	CTNNB1	Fusion	ULK4--CTNNB1			0.0	0.0																					0				ULK4--CTNNB1 Fusion		MEL-IPI_Pat119		
Biologically Relevant				Rearrangement	MLH1	Fusion	MT-RNR2--MLH1			0.0	0.0																					0				MT-RNR2--MLH1 Fusion		MEL-IPI_Pat119		
Biologically Relevant				Rearrangement	RB1	Fusion	AC104820.2--RB1			0.0	0.0																					0				AC104820.2--RB1 Fusion		MEL-IPI_Pat119		
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G1196R	0.40700000000000003	199.0	5.7999999999999994e-05	0.0																					0	0.0	0.0	0.0	ROS1 p.G1196R (Missense)		MEL-IPI_Pat119	MEL-IPI_Pat119-Tumor-SM-7459N	MEL-IPI_Pat119-Normal-SM-7459Q
Biologically Relevant				Copy Number	RAD51B	Deletion				0.0	0.0																					0				RAD51B Deletion		MEL-IPI_Pat119	MEL-IPI_Pat119-Tumor-SM-7459N	
Biologically Relevant				Copy Number	ATM	Deletion				0.0	0.0																					0				ATM Deletion		MEL-IPI_Pat119	MEL-IPI_Pat119-Tumor-SM-7459N	
Biologically Relevant				Microsatellite Stability	Supporting variants		DOCK3 p.Q138* (Nonsense), MT-RNR2--MLH1 Fusion, MITF--MSH3 Fusion																									0				Supporting variants: DOCK3 p.Q138* (Nonsense), MT-RNR2--MLH1 Fusion, MITF--MSH3 Fusion		MEL-IPI_Pat119		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.495																									0				COSMIC Signature (version 2) 7 (50%)		MEL-IPI_Pat119		
